5 unknown, 3 not yet recruiting, 3 recruiting, 2 active not recruiting. 6 Phase 2, 3 Not applicable, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Active not recruiting 1, Completed 1, Unknown 1 |
| Not applicable | 3 | Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 4 | 3 | Unknown 2, Not yet recruiting 1 |
Follow nas: new trials by email Literature Review of nas trials Research Report on nas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha PEG IFNα-2b monotherapy or combination therapy with NAs, NAs monotherapy group - Chronic Hepatitis b | Not yet recruiting | xieqing | 10000 | 2026-04-30 | 2026-04-17 | |
| A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis Peginterferon alfa-2b combined with NAs, NAs - HBV-related Liver Cirrhosis | Not applicable | Not yet recruiting | Xiamen Humanity Hospital | 30 | 2025-10-01 | 2025-09-19 |
| Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients Peg-IFN α-2b combined with NAs - Metabolic Dysfunction-Associated Steatotic Liver Disease, Chronic Hepatitis B | Phase 4 | Not yet recruiting | Shenzhen Third People's Hospital | 830 | 2025-08-15 | 2025-07-17 |
| Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB) AHB-137, NAs, Placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Ausper Biopharma Co., Ltd. | 105 | 2024-12-13 | 2026-07-29 |
| Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection TQA3605 tablets plus NAs, TQA3605 Placebo plus NAs - HBV Infection With LLV | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 122 | 2024-11-14 | 2026-01-26 |
| Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients Sintilimab, NAs, Peg-IFNα-2b - Chronic Hepatitis B | Not applicable | Unknown | Beijing 302 Hospital | 50 | 2024-06-15 | 2024-06-20 |
| The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients Sintilimab, Peg-IFNα-2b, NAs - Chronic Hepatitis B | Not applicable | Active not recruiting | Beijing 302 Hospital | 45 | 2024-05-17 | 2026-03-18 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B) Anti-PD-1 antibody, NAs, Peg-IFNα - Chronic Hepatitis b, Anti-PD-1 Antibody | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2023-10-10 | 2026-09-04 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B) anti-PD-1/anti-PD-L1 antibody, NAs, PEG-IFNα - Chronic Hepatitis B, Anti-PD-1 Antibody | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 1200 | 2023-10-10 | 2026-09-28 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A) Anti-PD-1 antibody, NAs - Chronic Hepatitis b, Anti-PD-1 Antibody | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2023-10-10 | 2026-09-22 |
| Nursing Activity Score (Nursing Activities Score-NAS) Verification of Turkish Version NAS - Nurse's Role | Completed | Samsun University | 150 | 2023-05-05 | 2024-01-16 | |
| Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy Interferon, nucleoside analogues - Chronic Hepatitis B, COVID-19 Infection | Unknown | Beijing Ditan Hospital | 600 | 2022-09-01 | 2023-03-31 | |
| Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients pegylated interferon (Peg IFN)α-2b, Nucleoside （acid）analogue (NAs) - Cirrhosis of Liver Due to Hepatitis B (Disorder) | Phase 2 | Unknown | Sun Yat-sen University | 84 | 2019-06-17 | 2019-06-20 |
| The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg Peginterferon Alfa, Nucleoside Analog (Substance) - Chronic Hepatitis B | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 200 | 2019-01-01 | 2019-01-15 |
| The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg peginterferon alfa, Nucleoside analogues - Chronic Hepatitis B | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 200 | 2016-06-01 | 2019-01-15 |
Hepatitis B, Chronic (11) · COVID-19 (1) · Hepatitis, Chronic (1)
The Second Affiliated Hospital of Chongqing Medical University (3) · Beijing 302 Hospital (2) · Third Affiliated Hospital, Sun Yat-Sen University (2) · Ausper Biopharma Co., Ltd. (1) · Beijing Ditan Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Samsun University (1) · Shenzhen Third People's Hospital (1) · Sun Yat-sen University (1) · Xiamen Humanity Hospital (1) · xieqing (1)
China (13) · Turkey (Türkiye) (1)
Hong Ren, MM (3) · Bingliang Lin, Doctor (1) · Qing Xie (1) · Wenqi Huang (1) · Yao Xie, Doctor (1) · Zhiliang Gao (1) · Zhiliang Gao, Doctor (1)